Objective:To investigate the clinical relevance of ATF3 and prostate cancer.Methods:Bioinformatic analyses were employed to determine genetic alterations of ATF3 in prostate cancer.Immunohistochemical staining was used to validate the ATF3 expression pattern in benign prostate tissues and prostate cancer tissues.Correlation analyses were performed to show clinical relevance of ATF3 expression and clinical features.Survival outcomes were also predicted which were derived from the TCGA dataset.Results:ATF3 is significantly amplified in prostate cancer and ATF3 expression is higher in prostate cancer tissues.High ATF3 expression is associated with disease progression and metastasis.Patients with high ATF3 burden show worse clinical outcomes.Conclusions:ATF3 is closely related with disease progression and clinical outcomes which can be served as a biomarker of prostate cancer.
prostate cancerATF3immunohistochemistryprostate specific antigen
NETL
NSTL
万方数据
